長春高新(000661.SZ)2020年度淨利潤升71.64%至30.47億元 擬10派8元
格隆匯 3 月 11日丨長春高新(000661.SZ)發佈2020年年度報吿，實現營業收入85.77億元，同比增長16.31%；歸屬於上市公司股東淨利潤30.47億元，同比增長71.64%；歸屬於上市公司股東的扣除非經常性損益的淨利潤29.52億元，同比增長66.25%；基本每股收益7.53元，擬每10股派發現金紅利8元(含税)。經營活動產生的現金流量淨額11.11億元，同比下降42.57%。
公司主營業務為生物製藥及中成藥的研發、生產和銷售，輔以房地產開發、物業管理和服務等業務。公司經過多年的產業佈局和研發投入，醫藥產品覆蓋創新基因工程製藥、新型疫苗、現代中藥等多個醫藥細分領域，是公司業績的主要來源。房地產業務進行有計劃的土地儲備，立足特色地產開發與經營。具體如下：
子公司金賽藥業主要從事基因工程生物藥品的研發、生產和銷售，主要產品為注射用重組人生長激素(粉針劑)、重組人生長激素注射液(水針劑)、聚乙二醇重組人生長激素注射液(長效水針劑)等人生長激素系列產品及輔助生殖、婦女健康等領域產品。金賽藥業實現收入58.03億元，同比增長20.34%；實現淨利潤27.60億元，同比增長39.66%。
子公司百克生物主要從事人用疫苗的研發、生產和銷售，目前百克生物及其子公司邁豐生物共有三種已獲批上市的疫苗產品，包括水痘減毒活疫苗、人用狂犬病疫苗(Vero細胞)(液體)、凍幹鼻噴流感減毒活疫苗(凍幹)。子公司百克生物實現收入14.33億元，同比增長43.30%；實現淨利潤4.09億元，同比增長133.88%。
子公司華康藥業主要從事中藥的研發、生產和銷售，涵蓋心腦血管、中藥抗炎及婦兒等產品線，主要產品包括血栓心脈寧、銀花泌炎靈、疏清顆粒、清胃止痛微丸等。華康藥業實現收入5.83億元，同比增長0.45%；實現淨利潤0.42億元，同比降低1.48%。
子公司高新地產主要從事房地產的開發及銷售，多年來立足特色地產開發與經營，在長春市先後開發了高新·怡眾名城、高新·和園、高新·慧園、高新·君園、高新·海容廣場等項目。高新地產實現收入7.25億元，同比下降23.00%；實現淨利潤1.37億元，同比降低41.62%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
